A 6-year-old child with a history of seizures, developmental delay, and light skin pigmentation is found to have elevated plasma phenylalanine on routine screening. The child was born in a remote area without access to neonatal screening. Which is the most common site of enzyme deficiency in phenylalanine metabolism disorders?

Explanation

## Most Common Site of Enzyme Deficiency in Phenylalanine Metabolism **Key Point:** The **liver** is the primary and most common site of enzyme deficiency in phenylalanine metabolism disorders. Phenylalanine hydroxylase (PAH), the rate-limiting enzyme of phenylalanine catabolism, is predominantly expressed in hepatic tissue. ### Hepatic Localization of Phenylalanine Hydroxylase **High-Yield:** Phenylalanine hydroxylase is a hepatic enzyme with the following characteristics: - **Tissue distribution:** ~90% of PAH activity is in the liver; minor activity in kidney and intestine - **Cofactor requirement:** Requires tetrahydrofolate (BH~4~) as a cofactor - **Reaction:** Catalyzes the hydroxylation of phenylalanine to tyrosine via a mixed-function oxidase mechanism $$\text{Phenylalanine} + \text{BH}_4 + \text{O}_2 \xrightarrow{\text{PAH (liver)}} \text{Tyrosine} + \text{dihydrofolate}$$ ### Why Liver Is the Primary Site **Clinical Pearl:** The liver is the metabolic hub for amino acid catabolism. Phenylalanine, like most amino acids, is metabolized primarily in the liver via: 1. Transamination (phenylalanine aminotransferase) 2. Hydroxylation (phenylalanine hydroxylase) — the major pathway 3. Oxidative deamination When hepatic PAH is deficient, phenylalanine accumulates systemically because there is no alternative pathway of sufficient capacity to clear it. ### Comparison of Phenylalanine Metabolism Sites | Site | Enzyme | Function | Contribution to Phe Catabolism | | --- | --- | --- | --- | | **Liver** | Phenylalanine hydroxylase (PAH) | Primary hydroxylation to tyrosine | ~90% (rate-limiting) | | Kidney | Minor PAH activity, transaminase | Secondary metabolism | ~5–10% | | Intestine | Phenylalanine aminotransferase | Transamination | Minimal | | Brain | Tyrosine hydroxylase (not PAH) | Converts tyrosine to L-DOPA | Consumes tyrosine, not Phe | ### Clinical Correlation: Why Liver Disease Matters **Key Point:** Patients with advanced liver disease (cirrhosis, hepatic failure) may develop secondary hyperphenylalanemia due to loss of hepatic PAH function, even without a genetic mutation. This is distinct from primary PKU but highlights the liver's central role. ### Phenotype-Genotype Correlation Classical PKU results from **biallelic loss-of-function mutations in the PAH gene** (chromosome 12q23.2). Over 1,000 mutations have been described, ranging from: - **Severe mutations:** Complete loss of PAH activity (classical PKU, Phe >1200 µmol/L) - **Mild mutations:** Residual PAH activity (mild hyperphenylalaninemia, Phe 120–600 µmol/L) **Mnemonic: LIVER is the site — L = Location of PAH, I = Intestine/kidney minor, V = Vital for Phe clearance, E = Essential cofactor BH₄, R = Rate-limiting enzyme** ### Why Other Sites Are Not Primary - **Kidney:** Has minor PAH activity but cannot compensate for hepatic deficiency - **Brain:** Expresses tyrosine hydroxylase (converts tyrosine → L-DOPA), not PAH; does not metabolize phenylalanine - **Intestine:** Lacks significant PAH; phenylalanine is absorbed and transported to liver for metabolism